Clinical and translational advances in ovarian cancer therapy
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
L Zhong, Y Li, L ** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …
A Poveda, A Floquet, JA Ledermann, R Asher… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …
been shown to extend progression-free survival versus placebo when given to patients with …
PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …
processes, including the regulation of transcription, apoptosis and the DNA damage …
Poly (ADP-ribose) polymerase inhibition: past, present and future
The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …